Novo Nordisk said on Monday it would halt its collaboration with U.S. telehealth company Hims & Hers Health over the ...

Novo Nordisk unveiled its latest data for a weight-loss drug candidate, but shares of the maker of Wegovy and Ozempic tumbled ...

Novo Nordisk said Hims & Hers has “failed to adhere to the law which prohibits mass sales of compounded drugs” under the ...

Novo Nordisk said on Monday it would halt its collaboration with Hims & Hers Health over the sale of weight loss drugs.

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over ...

Hims stock took a major hit after Novo Nordisk suddenly ended their Wegovy partnership, causing shares to drop over 20% in a single day. The breakup came after Novo raised concerns about Hims selling ...

Novo Nordisk said in a statement on Monday that direct access to Wegovy would no longer be available to Hims & Hers Health ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

Hims & Hers Health Inc.’s stock fell sharply on Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug ...

Novo Nordisk announced it will stop collaborating with Hims & Hers Health regarding the distribution of Wegovy weight loss ...